Last reviewed · How we verify
Prescription drugs with known hepatotoxicity — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Prescription drugs with known hepatotoxicity (Prescription drugs with known hepatotoxicity) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Prescription drugs with known hepatotoxicity TARGET | Prescription drugs with known hepatotoxicity | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Prescription drugs with known hepatotoxicity CI watch — RSS
- Prescription drugs with known hepatotoxicity CI watch — Atom
- Prescription drugs with known hepatotoxicity CI watch — JSON
- Prescription drugs with known hepatotoxicity alone — RSS
Cite this brief
Drug Landscape (2026). Prescription drugs with known hepatotoxicity — Competitive Intelligence Brief. https://druglandscape.com/ci/prescription-drugs-with-known-hepatotoxicity. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab